Additionally, YB-1 (Y-box binding protein 1) enhances Sorafenib resistance in HCC by activating the PI3K/AKT signaling pathway, highlighting its association with drug resistance [3]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.